OR WAIT 15 SECS
Pharmaceutical Executive
October 29, 2008
News Analysis
0
Affiris struck a deal with GlaxoSmithKline to develop two Alzheimer's treatments. As part of the agreement, GSK gains a fancy protein technology that could be a boon for future molecules.